A recent meta-analysis reported smoking to be associated with a 37% higher risk of type 2 diabetes in current smokers, rising to a 57% increase in heavy smokers, which declines on quitting. If the increase results from nicotine exposure, it is possible that using Swedish moist snuff ("snus"), which provides at least equivalent nicotine doses, might also increase diabetes risk. Following a recent publication reporting pooled results from five cohorts, we present a detailed meta-analysis of data from 18 studies. Based on covariate-adjusted estimates, no significant increased risk was seen in never smokers with RRs (95% CIs) of 1.08 (0.86-1.34), 0.93 (0.79-1.11) and 1.05 (0.94-1.18) for current, former and ever snus users. Significant increases were also not seen in the whole population, the corresponding RR estimates being 1.18 (0.94-1.48), 0.69 (0.49-0.96) and 0.95 (0.81-1.11). Nor was there an association of snus use with related endpoints, such as impaired glucose tolerance. However, dose-response analyses showed a relationship, with the highest levels of snus exposure associated with a diabetes RR of 1.65 (1.25-2.18) in never smokers. The evidence relating snus to type 2 diabetes is somewhat limited, requiring further studies to confirm any possible relationship.
Introduction
In 2011, in this journal, one of us (P.N. Lee) reviewed the epidemiological evidence relating snus to health (Lee, 2011) , noting that there was "scant support for any major adverse health effect of snus". Although it was noted that "snus users have increased weight" the review concluded that diabetes seems to be "unaffected", and a lack of relationship with heart disease risk was also demonstrated. The section on diabetes cited 10 relevant publications (Attvall et al., 1993; Eliasson et al., 1995 Eliasson et al., , 2004 Eliasson et al., , 1991 Hergens et al., 2005; Johansson et al., 2005; Norberg et al., 2006; Persson et al., 2000; Wallenfeldt et al., 2001; Wändell et al., 2008) which noted that, despite occasional reports of significant associations, there was generally no clear or consistently observed relationship of snus use with diabetes or a range of associated endpoints, such as glucose intolerance, fasting glucose levels, fasting insulin levels, or metabolic syndrome. However, meta-analyses were not attempted.
Elsewhere, it has also been reported that the fasting blood glucose levels of snus users are not significantly different from those for never users (Foulds et al., 2003) . However, our conclusion that an association of snus with diabetes was "not clearly established" contrasts with that from a pooled analysis of results from five cohorts (Carlsson et al., 2017) which concluded that "high consumption of snus is a risk factor for type 2 diabetes". This analysis estimated that, compared to never users the confounder-adjusted hazard ratio (HR) was 1.15 (95% CI 1.00-1.32) in current users of snus, rising to 1.68 (1.17-2.41) in users of seven or more boxes per week.
Preliminary inspection of the results of the analysis suggested that the significantly increased risk in current users derived principally from the results in one of the five cohorts considered, the Våsterbotten Intervention Programme (VIP), where the HR was 1.28 (95% confidence interval [CI] 1.08-1.52), no significant increase being seen in one of the other cohorts, and no increase at all in the other three, though two of these estimates were based on less than 10 diabetes cases in current users. However, the results for heavy consumers were more consistent, with an elevated risk seen in all four cohorts with dose-response data, though statistically significantly only for the VIP.
While Carlsson et al. (2017) refer to some of the publications we cited (Eliasson et al., 1995 (Eliasson et al., , 2004 Persson et al., 2000) and to results of some more recent studies on diabetes (Östenson et al., 2012; Rasouli et al., 2016) , they did not attempt a meta-analysis of the overall literature. The objective of this publication is to present such a metaanalysis.
Materials and methods

Literature searching
Relevant papers were derived from PubMed searches of (snuff OR snus OR smokeless tobacco) AND (diabetes OR glucose intolerance OR insulin) initially conducted on 14th February 2017, and updated on 5th September 2017. Abstracts were studied initially, with papers of potential interest then looked at. Relevant reviews were also studied for relevant references as were reference lists in papers identified. The objective was to identify papers that presented evidence on the relationship of snus use, in never smokers and/or in the whole population, to diabetes or to associated endpoints, such as impaired glucose tolerance or fasting glucose or insulin resistance or response. A similar Embase search was conducted on 8th September, looking for additional relevant papers.
Data extraction
For each study identified, information was extracted on the study name and location, relevant references, study design (prospective, casecontrol or cross-sectional), subjects included, sexes studied, endpoints studied and confounding variables adjusted for. For each endpoint for which results were available, relative risks (RRs), odds ratios (ORs) or HRs were extracted, or derived from data presented using standard methods (Gardner and Altman, 1989; Hamling et al., 2008; Lee et al., 2012) . Estimates were extracted for current, former and ever snus users relative to never snus users, separately for never smokers and for the whole population. Where available, estimates were extracted (or derived) adjusted for the maximum number of potential confounding variables for which results were available, and also unadjusted for any variable (for case-control and cross-sectional studies) or for age only (for prospective studies). Estimates were also extracted (or derived) by extent of exposure to snus. For diabetes in never smokers, estimates were also made of the increase in RR per box used per week.
Exceptionally, some studies only reported results for continuous endpoints, such as blood glucose or insulin. Here the findings were summarized from the relevant publications.
Meta-analyses
Meta-analyses were only carried out for diabetes, separately for current, former and ever snus use, based on results either for never smokers or the whole population. Meta-analysis was mainly restricted to effect estimates which were adjusted for confounding variables. Standard methods were used to carry out the meta-analyses (Fleiss and Gross, 1991) with fixed-effect and random-effects estimates computed, together with a test for heterogeneity between individual estimates. Estimates were derived using all the available data for a particular analysis, and also for subsets of the data by time of publication (to 2010, 2011 onwards) , study design (case-control or cross-sectional, prospective), type of diabetes (type 2, unspecified), number of potential confounding variables adjusted for (≤4, 5+), and number of cases of diabetes in exposed subjects (≤10, 11 + for analyses of current and former snus use, and ≤20, 21 + for analyses of ever snus use). Publication bias was also investigated using Egger's test (Egger et al., 1997) . (Persson et al., 2000) 2000 Sweden, Stockholm CS General population M 52 T2D IGT, IRESIS, IRESP AIR (Wallenfeldt et al., 2001) 2001 Sweden, Göteborg CS General population M --BGL, INP MONICA I (Eliasson et al., 1995; Eliasson et al., 2004) (Östenson et al., 2012) 2012 Sweden, Stockholm County P (12) General population M 99 T2D -ESTRID (Rasouli et al., 2016) 2016 Sweden, Scania and Uppsala CC General population M 724 T2D LADA HUNT (Rasouli et al., 2016) 2016 Norway, Nord-Trøndelag county CS General population M 829 T2D -VIP (Carlsson et al., 2017; Neumann et al., 2013; Norberg et al., 2006) 2017 Sweden, Våsterbotten County
SPHC (Carlsson et al., 2017) 2017 Sweden, Stockholm County P (10) General population M 237 T2D -SALT (Carlsson et al., 2017) 2017 Sweden, nationwide P (12) Twins M 405 T2D -MDCS (Carlsson et al., 2017) 2017 Sweden, Malmö P (21) General Population M 461 T2D -NMC (Carlsson et al., 2017) 2017 Sweden, nationwide P (13) Participants in fundraising event M 305 T2D -NSC (Byhamre et al., 2017; Gustafsson et al., 2011) 
Results
Literature searches
The first PubMed search produced 100 hits. Based on the abstracts, 83 were rejected as irrelevant. The remaining 17 papers were obtained for scrutiny, with four rejected as providing no additional primary data and one being a review. The remaining 12 papers were supplemented by an additional three publications identified in reviews or in reference lists of papers identified as relevant. The second PubMed search produced an additional five hits, four papers being rejected based on abstracts, with one recent relevant paper added to the 16 previously identified. The Embase search produced 179 hits, with only two additional papers obtained, both rejected as providing no additional primary data.
The studies
The 16 references described eighteen studies which provided evidence on the association between snus use and diabetes and related conditions. Table 1 gives details of the main characteristics of the studies, a more detailed description of each study being given in Appendix A. Two studies were published in the 1990s, seven between 2000 and 2010, and nine after 2011. Except for one study in Norway, all the studies were in Sweden. Seven studies were cross-sectional, while two were of a case-control design, both drawing controls from the general population. The remaining nine studies were prospective, with followup ranging from 10 to 27 years. Fifteen studies were in males, while two involved both sexes. One study only included women for certain endpoints.
Various endpoints were considered. Type 2 diabetes (T2D) was investigated in 12 studies, although one of these included impaired fasting glucose in their definition. A further three studies provided information on diabetes, but did not specify the type. Four studies used an endpoint of impaired glucose tolerance and/or pathological glucose tolerance, the latter being a combination of diabetes or impaired glucose tolerance. One study considered latent autoimmune diabetes of adulthood (LADA), and another study the metabolic syndrome. Blood glucose level was examined by four studies, with insulin level considered by three. One study also examined insulin resistance and response levels.
Three studies (Attvall et al., 1993; Eliasson et al., 1991; Wallenfeldt et al., 2001) , none of which provided information on diabetes, did not adjust their results for any potential confounding variables. In the remaining 15 studies (see Table 2 ), all but three considered age, although one of these studies did carry out a series of analyses in which they evaluated various endpoints at different ages. Various other confounders were considered, the most common being waist circumference, body mass index, alcohol consumption, smoking status, physical activity, education and family history of diabetes. Table 3 summarizes the evidence relating snus use in never smokers to covariate-adjusted risk of type 2 diabetes. Corresponding unadjusted (or for prospective studies age-adjusted results) are given in Appendix B, Table B1 . These tables also include overall meta-analysis results, with adjusted results separated by time of publication, study design, type of diabetes, number of confounding variables, and number of exposed cases shown in Appendix C, Table C1 . In these tables, the effects estimates are referred to as RRs, though they may have been estimated as ORs or HRs.
Diabetes
It can be seen from Table 3 that a number of the individual study effect estimates are based on quite small numbers of snus-exposed cases, with, for example, five of the 11 estimates for current use based on less than 10 cases. Also, the number of snus-exposed cases in the VIP study form over half the total number in all the studies combined. None of the random-effect estimates, whether for current, former or ever snus use show significant (p < 0.05) evidence of an effect, with the combined estimates being, respectively, 1.08 (95% CI 0.86-1.34), 0.93 (0.79-1.11) and 1.05 (0.94-1.18). Nor was there any significant evidence of heterogeneity between estimates, despite two of the estimates for current use (from the SDPP1 and VIP studies) being statistically significantly increased, or of publication bias (data not shown). There was an indication that case-control or cross sectional studies produced somewhat higher results for current snus use, with the overall estimate for these four studies being 1.40 (0.86-2.31), compared to 1.14 (0.99-1.30) for the seven prospective studies (see Table C1 ). However, this difference was not statistically significant (p = 0.42), and was scarcely evident for former or ever snus use. There was no evidence that estimates varied significantly by year of publication, type of diabetes, number of confounding variables considered, or number of exposed cases. The overall unadjusted estimates (see Table B1 ) tended to be somewhat lower, at 0.93 (0.82-1.05), 0.65 (0.39-1.09) and 0.69 (0.52-0.94) for, respectively, current, former and ever snus use. The low estimates for former and ever snus use, and the substantial heterogeneity for these estimates, are largely due to particularly low unadjusted estimates from the ESTRID study. Table 4 , B2 and C2 similarly summarize the evidence relating snus use in the whole population to risk of type 2 diabetes. The numbers of snus-exposed cases shown in Table 4 remain quite small, except in the ESTRID and HUNT studies. Again, none of the overall random-effect estimates, 1.18 (95% CI 0.94-1.48) for current use, 0.69 (0.49-0.96) for former use and 0.95 (0.81-1.11) for ever use show any significant evidence of an increased risk with snus use, the estimate for former use indicating a significantly decreased risk, though relying primarily on the results from the ESTRID study. There was no significant evidence of heterogeneity for current, former or ever use. The tests for publication bias were not significant except for current use, where five estimates above 1.0 from relatively small studies were countered by a slightly reduced estimate from the ESTRID study. Results based on case-control or cross-sectional studies did not vary significantly from those based on prospective studies, for current, ex-or ever snus use (see Table C2 ). There was also little indication that the effect estimates varied by level of the other factors considered, though for ever use there was marginally significant (0.01 < p < 0.05) evidence of higher effect estimates in earlier studies, in studies where the type of diabetes was unspecified, and in smaller studies, though these comparisons were not independent of each other. The overall unadjusted estimates (see Table B2 ) were here quite similar to the adjusted ones, being 1.16 (0.90-1.51), 0.82 (0.63-1.09) and 0.96 (0.71-1.30) for, respectively, current, former and ever use. The significant heterogeneity for ever use derives from the low effect estimate for the HUNT study. Table 5 summarizes available dose-response results from 11 studies, eight presenting results for never smokers and five for the whole population. The results presented are for various dose metametersboxes/wk, cans/wk, box-years, duration (in years) and periods of follow-up -and for various dose levels. Significant increases, compared to never users, at the highest level of exposure are seen for never smokers in two studies (SDPP1 for 3 + boxes/wk and VIP for 7 + boxes/wk) and for the whole population in one study (SDDP2 for 5 + boxes/wk). Meta-analyses of the effect at the highest level were carried out both for never smokers and for the whole population, preferring estimates for boxes/wk, where a single study gave results for multiple dose metameters. For never smokers, the random-effects analysis showed clear evidence of an association, with a combined estimate of 1.65 (95% CI 1.25-2.18) based on eight independent estimates and no significant heterogeneity. The largest contributors to the overall estimate were the estimates of 2.70 (1.30-5.50) from the SDPP1 study and of 1.79 (1.14-2.80) from the VIP study, the combined estimate becoming non-significant, at 1.31 (0.87-1.98), based on the other six estimates. For the whole population, the combined evidence from the highest level of exposure was a non-significant 1.20 (0.71-2.04), based on four somewhat variable estimates (heterogeneity p = 0.0528). For diabetes in never smokers, where RRs are available by the number of boxes of snus used per week, Table 5 shows the estimated increase in RR per box per week. Based on these seven estimates, a combined fixed-effect estimate of 1.05 (95% CI 1.02-1.08) was derived. Although there was no significant heterogeneity between the individual increases, the overall estimate was again heavily dependent on the increases seen in the SDPP1 and VIP studies.
Other endpoints
The evidence relating snus use to other endpoints in never smokers which is summarized in Table 6 is sparse, but is not at all indicative of a positive relationship with snus use, with none of the ten estimates statistically significant, and only two of them above 1. Although one of the 17 estimates for other endpoints in the whole population shown in Table 7 shows a significant increase (RR 2.2, 95% CI 1.1-4.4) this, for insulin response, is for former snus users, with no significant increase seen in this study for current users. The overall evidence shown in the Table is not suggestive of an effect of snus, with 12 of the 17 estimates below 1.
Not included in Tables 6 and 7 are results from four studies which reported results relating snus use to blood glucose and insulin levels. In the first study (Eliasson et al., 1991) , snus use had no effect on blood glucose levels, but serum insulin was higher in snus users (5.5 mU/L) than in non-tobacco users (3.6 mU/L) and this difference was statistically significant (p < 0.01). The second study (Attvall et al., 1993 ) also reported no difference in blood glucose levels or in fasting insulin levels before or after normoglycaemic clamps. The third study (Wallenfeldt et al., 2001 ) reported no significant difference in fasting blood glucose or plasma insulin between current, ex-or never snus users. The MONICA I study (Eliasson et al., 1995) found no differences between non-tobacco users and snus users in fasting glucose levels, fasting insulin or post-load insulin. The limited dose-response evidence for other endpoints, shown in Table 8 , provides no real indication of an effect of snus on any of the endpoints studied.
Discussion
A recent meta-analysis of prospective studies relating smoking to diabetes risk (Pan et al., 2015) reported combined results from 88 prospective studies involving almost 300,000 incident cases of type 2 diabetes. Significant combined estimates were noted for current smokers (RR 1.37, 95% CI 1.33-1.42), former smokers (1.14, 1.10-1.18) and never smokers exposed to environmental tobacco smoke (1.22, 1.10-1.35). A dose-response relationship was also noted for current smoking, with an estimate of 1.57 (1.47-1.66) for heavy smokers. Risk estimates declined with time quit. Given that snus users have levels of nicotine exposure that are similar to, and perhaps somewhat greater than, that from smoking (Lee, 2011) , the possibility arises that snus use might, if nicotine is relevant to risk of diabetes, also increase risk of diabetes.
The evidence that snus use increases the risk of type 2 diabetes is clearly much weaker for snus than for smoking. Thus, there is no significant evidence of an increased risk, compared to never snus users, in current, former or ever snus users, whether restricting attention to never smokers or considering the whole population. Nor is there any clear evidence of an association of snus use with endpoints related to diabetes, such as glucose or insulin levels. The only real evidence for a possible effect of snus on diabetes arises from the dose-response data, where in never smokers (though not in the whole population) there is an increased RR of 1.65 (95% CI 1.25-2.18) for the highest level of current snus use, and a RR of 1.05 (1.02-1.08) can be derived for the increase in RR per extra box of snus used per week.
In considering the evidence on snus, various issues should be considered. Firstly, only 15 studies provide data on snus and diabetes, far less than the 88 studies considered in the recent review of smoking and diabetes (Pan et al., 2015) . Furthermore, many of the estimates are based on rather small numbers of snus-exposed cases, with the VIP study on its own providing more than half the exposed cases for never Table 4 Risk of type 2 diabetes and snus use in the whole population (adjusted for variables given in Table 2 (Persson et al., 2000) Never smokers Boxes/wk 0,1-2,3+ 1.00 0.20 (0.00-2.00) 2.70 (1.30-5.50) 1.17 (1.04-1.32) Stockholm County (Wändell et al., 2008) (Carlsson et al., 2017) Never smokers Boxes/wk 0,1-2,3-4, 1.00 1.12 (0.81-1.54) 1.17 (0.89-1.52) 5-6,7+
1.48 (1.09-2.02) 1.79 (1.14-2.80) 1.06 (1.03-1.10) Duration (yr) 0, < 30,30+ 1.00 1.40 (1.06-1.84) 1.22 (1.00-1.51) SPHC (Carlsson et al., 2017) Never smokers Boxes/wk 0,1-2,3-4, 1.00 No cases 1.50 (0.45-5.00) 5-6,7+ 2.62 (0.62-11.02) 1.50 (0.20-11.28) 1.10 (0.95-1.27) Duration (yr) 0, < 30,30+ 1.00 1.96 (0.45-8.58) 1.17 (0.41-3.36) SALT (Carlsson et al., 2017) Never smokers Boxes/wk 0,1-2,3-4, smokers (see Table 3 ) and the ESTRID and HUNT studies contributing largely to the results for the whole population (see Table 4 ). With the single exception of the HUNT study in Norway, the studies are all conducted in Sweden, so that variation between countries in the product used is unlikely to be an issue. Many, but not all of the studies, adjusted for a range of potential confounding variables, though little evidence was provided on which specific variables materially affected risk estimates. While 12 of the 15 studies provided results specifically for type 2 diabetes, three studies (SHEP/VHEP, SALLS and Stockholm County) only referred to diabetes. However, there was no evidence that results varied significantly by definition of diabetes. Nor was there evidence that results varied by other factors considered, including time of publication, study design, number of potential confounding variables adjusted for, or number of cases in snus-exposed subjects. This suggests that it is reasonable to take the overall estimates shown in Tables 3 and  4 as indicative of the relationship between snus and diabetes. The extent to which these estimates might be affected by various biases is difficult to assess. We found no evidence of publication bias using the Egger test, although this test has limited power when few studies are available. We were unable to formally take into account possible biases arising from misclassification of disease or of exposure (to snus or smoking), though it seems doubtful whether these would have any major effect. As all but one of the studies was conducted in Sweden, some overlap between studies is possible. However, we consider it unlikely to be is a major issue. Studies sharing a location tended to differ either in the time period during which they were conducted or the endpoint considered, or the population was more narrowly defined in some studies, meaning that only a small number of subjects were likely to have participated in multiple studies. Only for the SDPP and SHEP/VHEP studies does it appear possible that more significant overlap may be present, as the studies included a similar age range and took place at the same time. SDPP I and II were limited to four municipalities in Stockholm county whereas SHEP/VHEP appears to include the whole county but there is no indication from the authors that the SDPP studies are a subset of SHEP/VHEP. There are enough differences between them in age range, study period and geographical location to consider them as separate studies, any overlap probably being quite small.
The main evidence of a relationship of snus to diabetes comes from the dose-response analyses. Though, for the whole population, the combined estimate for the highest level of exposure was not significant (RR 1.39, 95% CI 0.79-2.46) this was based on four rather variable estimates. Evidence of a dose-response was clearer for never smokers, with the combined RR estimate being 1.65 (95% CI 1.25-2.18), based on eight estimates, with no significant heterogeneity. As different studies reported dose-response results in different ways, four of the estimates were for 7 + boxes/wk, one for 5 + boxes/wk, two for 3 + boxes/wk, and one for 30 + years duration. Of these eight estimates, seven were above 1.00, with two (from the SDPP1 and VIP studies) statistically significant.
Based on pooled results from the VIP, SPHC, SALT and MDCS studies, a recent review (Carlsson et al., 2017) reported a significant increased risk of type 2 diabetes for 7 + boxes/wk (RR 1.68, 95% CI 1.17-2.41) and 5-6 boxes/wk (1.42, 1.07-1.87), and concluded that "high consumption of snus is a risk factor for type 2 diabetes", with a risk "similar to that in smokers" and supporting "the notion that nicotine increases the risk of type 2 diabetes." Although the findings of a dose-response in never smokers is indicative of a possible relationship of snus to diabetes risk, the general lack of association seen in the other analyses reported in this review suggests to us that more evidence is required before any firm conclusion can be reached. We note that the increased risk for 7 + boxes/wk reported in the review is heavily dependent on results from the VIP study -the combined results from the other three studies giving a non-significant estimate of 1.49 (0.80-2.75).
Conclusions
We found no evidence of an overall increased risk of type 2 diabetes in current, former or ever snus users, either in never smokers or the whole population. Nor is snus use associated with endpoints related to diabetes. There is some evidence of a dose-response relationship with diabetes risk, in never smokers, though not the whole population, but this requires confirmation from additional studies.
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